Algernon NeuroScience Announces Successful Dosing of 2nd Cohort in Phase 1 DMT Clinical Study Post published:April 4, 2023 Post category:Press Release
Algernon NeuroScience Announces U.S. SEC Qualification of Regulation A+ Tier II Offering to Raise up to USD $10M Post published:April 3, 2023 Post category:Press Release
Algernon Pharmaceuticals Announces Launch of Rights Offering Post published:March 21, 2023 Post category:Press Release
Algernon NeuroScience Appoints Global TBI Expert and Former NFL Neurological Player Care Safety Director Dr. David Brody to Advisory Board Post published:March 2, 2023 Post category:Press Release
Algernon Pharmaceuticals Announces 4 for 1 Forward Share Split Post published:March 1, 2023 Post category:Press Release
Algernon NeuroScience Initiates Traumatic Brain Injury Research Program With DMT; Appoints Global TBI Expert as Advisor Post published:February 21, 2023 Post category:Press Release
Algernon NeuroScience Provides Update on Phase 1 DMT Clinical Study, Drug Found Safe to Proceed to Next Phase Post published:February 16, 2023 Post category:Press Release
Algernon NeuroScience Doses First Subject in Phase 1 DMT Clinical Stroke Study Post published:January 17, 2023 Post category:Press Release
Algernon Pharmaceuticals Appoints Dr. Peter Dicpinigaitis to Chronic Cough Advisory Board Post published:January 15, 2023 Post category:Press Release
Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company’s Psychedelic DMT Stroke Program; Files Form 1-A Offering Statement with U.S. SEC for Regulation A+ Offering Post published:January 3, 2023 Post category:Press Release